Choose Your News
Loading...
Thumbnail
One of Sherlock Biosciences' key technologies comes from the Broad Institute lab of Feng Zhang, who did some of the early work elucidating the DNA-modifying... [Read More]
"We don't think this market should be monetized," says the chair of the board. [Read More]
The $1.5 billion health-tech startup HeartFlow has a noninvasive test for heart disease based on machine learning analysis of CT scans. Two new studies are... [Read More]
HeartFlow has raised $467 million for a test to detect heart disease. Problem: It might not make patients better off. [Read More]
She got great care in the hospital, but getting care after she was discharged was "a nightmare." [Read More]
Right now, only one company is trying to develop a new type of cell therapy for cancer: Iovance Biotherapeutics, with a market cap of $1.3... [Read More]
Biogen's Chief Medical Officer calls the results "a shot in the arm." An analyst calls the noise "deafening." A doctor sees potential help for patients. [Read More]
Drugmakers Eisai and Biogen presented positive results of their much-anticipated experimental Alzheimer's drug BAN-2401 today at the Alzheimer's Association International Conference in Chicago. But doctors... [Read More]
"Even after only two and a half years of taking blood pressure lowering medication, this is a dramatic benefit to improve brain health, especially lowering... [Read More]
The National Institutes of Health is explaining how it will spend $500 million in research funds Congress appropriated to address the current opioid crisis. [Read More]
The markers it tracks "haven't been validated," says one doctor. [Read More]
More and more, hospitals and health care companies are addressing so-called "social determinants of health" like housing and food security in addition to providing traditional... [Read More]
The drug's list price is $6,900 per year, or $575 per monthly injected dose, lower than many market-watchers expected. [Read More]
Envision says it negotiates appropriate payments for emergency room care. Critics say its tactics are what's wrong with healthcare. [Read More]
Celsius Therapeutics will use techniques for constructing detailed profiles of individual cells to develop drugs for autoimmune diseases and cancer immunotherapies. [Read More]
"We're going to start doing it the same way we would talk to patients about getting a cholesterol check," the health system's president and CEO... [Read More]
RubiconMD CEO Gil Addo was inspired to found the company in 2013 after his grandmother was diagnosed with a brain tumor. [Read More]
Ultragenyx said the drug will have a net price of about $160,000 per year for children and $200,000 for adults (depending on body weight). [Read More]
The fast-food joint was converted into an outpatient MRI center before the technology was FDA-approved. In its story, find the history of a $50 billion... [Read More]
"It's not going to happen tomorrow, but [Amazon] could basically make PBMs irrelevant." [Read More]
Loading...
Preview